Table 3.

Secondary outcomes: vascular and physical function

Outcome	Vitamin K Mean (SD)	Placebo Mean (SD)	Treatment Effecta (95% CI)	P
Office systolic BP (mm Hg)
6 mo	139 (22)	134 (18)	0 (−5 to 5)	0.96
12 mo	139 (23)	137 (21)	−2 (−8 to 4)	0.58
Repeated measures			0 (−5 to 4)	0.86
Office diastolic BP (mm Hg)
6 mo	76 (11)	74 (10)	1 (−2 to 3)	0.65
12 mo	75 (10)	74 (10)	−1 (−4 to 1)	0.32
Repeated measures			0 (−3 to 2)	0.70
Augmentation index (%)
6 mo	24 (10)	23 (11)	0 (−2 to 2)	0.72
12 mo	25 (10)	25 (9)	0 (−2 to 2)	0.97
Repeated measures			0 (−2 to 2)	0.94
Log (NT-pro-BNP [pg/ml]), 12 mo	7.46 (1.29)	7.47 (1.53)	0.10 (−0.20 to 0.39)	0.51
SPPB
6 mo	9.3 (2.8)	9.6 (2.2)	0.1 (−0.5 to 0.7)	0.71
12 mo	9.1 (3.0)	9.8 (2.2)	−0.4 (−1.0 to 0.3)	0.29
Repeated measures			−0.1 (−0.6 to 0.4)	0.74
Grip strength (kg)
6 mo	24.0 (11.6)	25.5 (10.7)	−0.2 (−1.7 to 1.2)	0.75
12 mo	24.1 (11.9)	23.8 (10.6)	−0.2 (−2.1 to 1.8)	0.88
Repeated measures			−0.4 (−1.9 to 1.1)	0.59
Number with at least one fall	13	15
Falls per month of fall diary data (falls rate per mo)	18/759 (0.024)	128/795 (0.161)	0.147b (0.090–0.241)	<0.001

NT-pro-BNP, N-terminal pro B-type natriuretic peptide; SPPB, Short Physical Performance Battery.

^aAdjusted for age, sex, eGFR, site, and baseline values.

^bIncident rate ratio.